In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes

Xenobiotica

Volumn 32, Issue 11, 2002, Pages 1017-1031

  Rypka, M ^a   Vesely J ^a   Chmela, Z ^a   Riegrova D ^a   Cervenkova K ^a   Havliek L ^b   Lemr, K ^a   Hanus J ^c   Cerny B ^c   Lukes J ^d   Michalikova K ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

6 BENZYLAMINO 2 (3 HYDROXYPROPYLAMINO) 9 ISOPROPYLPURINE; BOHEMINE; COUMARIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; METHOXSALEN; PURINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; CYTOCHROME P450 3A; N DEMETHYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PURINE DERIVATIVE; STEROID HORMONE 7 ALPHA HYDROXYLASE; STEROID HORMONE 7-ALPHA-HYDROXYLASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE; URIDINE DIPHOSPHATE GLUCOSE; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG SYNTHESIS; DRUG TRANSFORMATION; LIVER MICROSOME METABOLISM; METABOLITE; MOUSE; NONHUMAN; OXIDATION; THIN LAYER CHROMATOGRAPHY; ANIMAL; CHEMICAL MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; IN VITRO STUDY; LIVER; LIVER MICROSOME; METABOLISM;

ANIMALIA; MAMMALIA;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, THIN LAYER; CYCLIN-DEPENDENT KINASES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER; MICE; MICROSOMES, LIVER; MODELS, CHEMICAL; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; PURINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEROID HYDROXYLASES; URIDINE DIPHOSPHATE GLUCOSE; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 18744370439     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825021000012600     Document Type: Article

References (44)

1. Belejová, M., Chmela, Z., Rypka, M., Lemr, K., Lukeš, J., Hanuš, J., Ulrichová, J. and Veselý, J., 1999, Metabolism of synthetic CDK-inhibitors in mammalian cells. Paper presented at the 15th Biological Days, 6-8 September, České Budějovice, Czech Republic; repr. J. Berger (ed.), Cells (České Budějovice: KOOP), p. 39.
2. Boogaards, J. J. P., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., Van Bladeren, P. J. and Walther, B., 2000, Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30, 1131-1152.
3. Bourrié, M., Meunier, V., Berger, Y. and Fabre, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes, Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
4. Buolamwini, J. K., 2000, Cell cycle molecular targets in novel anticancer drug discovery. Current Pharmaceutical Design, 6, 379-392.
5. Červenková, K., Belejová, M., Chmela, Z., Rypka, M., Riegrová, D., Michnová, K., Michalíková, K., Šúrová, I., Brejcha, A., Hanuš, J., Černy̌, B., Fuksovǎ, K., Havlíček, L., Veselý, J., 2002, In vitro glycosidation potential towards olomoucine-type cyclin-dependent kinase inhibitors in rodent and primate microsomes. Physiological Research, accepted for publication.
6. Červenková, K., Chmela, Z., Rypka, M., Lemr, K., Hanuš, J., Havlíček, L., Belejová, M., Lotková, H., Červinková, Z. and Veselý, J., 2000, Metabolism of cyclin-dependent kinase inhibitor bohemine at the cellular and subcellular levels. Paper presented at the 2nd FEPS Congress, 29 June-4 July 1999, Prague, Czech Republic; abst. Physiological Research, 49, P42.
7. Chang, Y. T., Gray, N. S., Rosania, G. R., Sutherlin, D. P., Kwon, S., Norman, T. C., Sarohia, R., Leost, M., Meijer, L. and Schultz, P. G., 1999, Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry and Biology, 6, 361-375.
8. Chauret, N., Gauthier, A., Martin, J. and Nicoll-Griffith, D. A., 1997, In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130-1136.
9. Chmela, Z., Veselý, J., Lemr, K., Hanu, J., Havlíček, L., Rypka, M., Kryštof, V., Ulrichová, J., Walterová, D., Fuksová, K., Lukeš, J., Kolářová, H., Strnad, M. and Lenobel, R., 1998, Metabolism of olomoucine, roscovitine, and bohemine in small laboratory rodents. Paper presented at the 1st International Conference on Inhibitors of Protein Kinases, 15-20 September, Warsaw, Poland; abst. Cellular and Molecular Biology Letters, 3, 280.
10. Chmela, Z., Veselý, J., Lemr, K., Rypka, M., Hanuš, J., Havlíček, L., Kryštof, V., Michnová, L., Fuksová, K. and Lukeš, J., 2001, In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in male mice: Glucosidation as the principal metabolic route. Drug Metabolism and Disposition, 29, 326-334.
11. Court, M. H., Von Moltke, L. L., Shader, R. I. and Greenblatt, D. J., 1997, Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharmaceutics and Drug Disposition, 18, 213-226.
12. Doostzadeh, J., Cotillon, A.-C., Benalychérif, A. and Morfin, R., 1998a, Inhibition studies of dehydroepiandrosterone 7α- and 7βhydroxylation in mouse liver microsomes. Steroids, 63, 608-614.
13. Doostzadeh, J., Cotillon, A.-C. and Morfin, R., 1998b, Hydroxylation of pregnenolone at the 7 alpha- and beta-positions by mouse liver microsomes. Effects of cytochrome p450 inhibitors and structure-specific inhibition by steroid hormones. Steroids, 63, 383-392.
14. Eagling, V. A., Tjia, J. F. and Back, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107-114.
15. Epstein, J., Plapinger, R. E., Michel, H. O., Cable, J. R., Stephani, R. A., Hester, R. J., Billington, C., Jr and List, G. R., 1964, Reactions of isopropyl methylphosphonofluoridate with substituted phenols. I. Journal of the American Chemical Society, 86, 3075-3084.
16. Fischer, P. M. and Lane, D. P., 2000, Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Current Medicinal Chemistry, 7, 1213-1245.
17. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L. and Eaton, D. L., 1994, Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Research, 54, 101-108.
18. García-Echeverría, C., Traxler, P. and Evans, D. B., 2000, ATP site-directed competitive and irreversible inhibitors of protein kinases. Medical Research Reviews, 20, 28-57.
19. Gray, A. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., Leclerc, S., Meijer, L., Kim, S.-H., Lockhart, D. J. and Schultz, P. G., 1998, Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science, 281, 533-538.
20. Gray, N., Detivaud, L. and Meijer, L., 1999, ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry, 6, 859-875.
21. Gu, J., Zhang, Q. Y., Genter, M. B., Lipinskas, T. W., Negishi, M., Nebert, D. W. and Ding, X., 1998, Purification and characterization of heterogously expressed mouse CYP2A5 and CYP2G1: Role in metabolic activation of acetaminophen and 2,6-dichlorobenzonitrile in mouse olfactory mucosal microsomes. Journal of Pharmacology and Experimental Therapeutics, 285, 1287-1295.
22. Havlíček, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G. and Strnad, M., 1997, Cytokinin-derived cyclin dependent kinase inhibitors: Synthesis and cdc2 activity of olomoucine and related compounds. Journal of Medicinal Chemistry, 40, 408-412.
23. Hickman, D., Wang, J. P., Wang, Y. and Unadkat, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monoxygenase activities. Drug Metabolism and Disposition, 26, 207-215.
24. Hocart, C. H., Letham, D. S. and PARKER, C. W., 1991, Substituted xanthines and cytokinin analogues as inhibitors of cytokinin N-glucosylation. Phytochemistry, 30, 2477-2486.
25. Honda, A., Salen, G., Matsuzaki, Y., Batta, A. K., Xu, G., Leitersdorf, E., Tint, G. S., Erickson, S. K., Tanaka, N. and Shefer, S., 2001, Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis. Journal of Biological Chemistry, 276, 34579-34585.
26. Jones, E. C. S. and Pyman, F. L., 1925, The relation between chemical constitution and pungency in acid amides. Journal of the Chemical Society, 127, 2588-2598.
27. Juvonen, R. O., Gynther, J., Pasanen, M., Alhava, E. and Poso, A., 2000, Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7- hydroxylases (CYP2A5 and CYP2A6). Xenobiotica, 30, 81-92.
28. Legraverend, M., Ludwig, O., Bisagni, E., Leclerc, S., Meijer, L., Giocanti, N., Sadri, R. and Favaudon, V., 1999, Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry, 7, 1281-1293.
29. Meijer, L., 2000, Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. Drug Resistance Updates, 3, 83-88.
30. Meijer, L., Leclerc, S. and Leost, M., 1999, Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacology and Therapeutics, 82, 279-284.
31. Michalíková, K., Michnová, L., Belejová, M., Chmela, Z., Rypka, M., Lemr, K., Havlíčk, L., Lukeš, J., Veselý, J. and Ulrichová, J., 1999, Enzyme systems involved in metabolism of purine-related cyclin-dependent kinase inhibitors. Paper presented at the 15th Biological Days, 6-8 September, České Budějovice, Czech Republic; abst. J. Berger (ed.), Cells (České Budějovice: KOOP), p. 97.
32. Newton, D. J., Wang, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specifities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
33. Otyepka, M., Kryštof, V., Havlíček, L., Iglerová, V., Strnad, M. and Koča, J., 2000, Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. Journal of Medicinal Chemistry, 43, 2506-2513.
34. Patten, C. J., Peterson, L. A. and Murphy, S. E., 1998, Evidence for metabolic activation of N-nitrosonornicotine and N-nitrosobenzyl methylamine by rat nasal coumarin hydroxylase. Drug Metabolism and Disposition, 26, 177-180.
35. Pelkonen, O., Maenpaa, J., Taavitsainen, P., Rautio, A. and Raunio, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203-1253.
36. Quintieri, L., Rosato, A., Napoli, E., Sola, F., Geroni, C., Floreani, M. and Zanvello, P., 2000, In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Research, 60, 3232-3238.
37. Raiford, L. C. and Clark, E. P., 1923, Diacyl derivatives of ortho-hydroxybenzylamine. Journal of the American Chemical Society, 45, 1738-1743.
38. Rendic, S., 2002, Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews, 34, 83-448.
39. Rosania, G. R. and Chang, Y.-T., 2000, Targeting hyperproliferative disorders with cyclin-dependent kinase inhibitors. Expert Opinion on Therapeutic Patents, 10, 215-230.
40. Sausville, E. A., Zaharevitz, D., Gussio, R., Meijer, L., Louarn-Leost, M., Kunick, C., Schultz, R., Lahusen, T., Headlee, D., Stinson, S., Arbuck, S. G. and Senderovicz, A., 1999, Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacology and Therapeutics, 82, 285-292.
41. Sielecki, T. M., Boylan, J. F., Beneld, P. A. and Trainor, G. L., 2000, Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation. Journal of Medicinal Chemistry, 43, 1-18.
42. Venkatakrishnan, K., Von Moltke, L. L. and Greenblatt, D. J., 2001. Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149-1179.
43. Veselý, J., Havlíček, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S. and Meijer, L., 1994, Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry, 224, 771-786.
44. Wilson, W. S. and LeBlanc, G. A., 2000, The contribution of hepatic inactivation of testosterone to the lowering of serum testosterone levels by ketoconazole. Toxicological Sciences, 54, 128-137.